The FDA Vaccines and Related Biological Products Advisory Committee agreed on the efficacy, immunogenicity and safety data of Merck & Co Inc’s . The clinical trials support the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and men aged 9 to 26 years for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

A new study published in The Lancet depicts that GlaxoSmithKline’s human papillomavirus (HPV) vaccine is highly effective at preventing precancerous cervical lesions that can lead to cervical cancer. The researchers said that the HPV-16/18 AS04-adjuvanted vaccine was as much as 98% effective against HPV-16/18, and between 37% and 54% effective against 12 other cancer-causing HPV types.

ImmunoVaccine Technologies‘ DepoVax, depot vaccine formulation, has shown positive results in pre-clinical phase. The patented product has achieved single-dose efficacy in the treatment of cancer and other infectious disease vaccine models. Based on a new approach that uses liposomes which encapsulate a target antigen and adjuvant, DepoVax relies on a hydrophobic oil carrier that enhances vaccine induced cell-mediated immunity significantly.

Merck’s cervical vaccine Gardasil has been approved by the U.S. Food and Drug Administration for protection against vaginal and vulvar cancers caused by Human Papilloma Virus (HPV) types 16 and 18 for females aged from 9 to 26. The vaccine is already used for prevention of cervical cancer, approval for which was given by FDA in 2006. Gardasil does not work if you are already infected when you become vaccinated. Women should undergo regular screening to get precancerous lesions detected and receive treatment before cancer.